% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Galldiks:811686,
      author       = {Galldiks, Norbert and Langen, Karl-Josef},
      title        = {{A}mino {A}cid {PET} – {A}n {I}maging {O}ption to
                      {I}dentify {T}reatment {R}esponse, {P}osttherapeutic
                      {E}ffects, and {T}umor {R}ecurrence?},
      journal      = {Frontiers in neurology},
      volume       = {7},
      issn         = {1664-2295},
      address      = {Lausanne},
      publisher    = {Frontiers Research Foundation},
      reportid     = {FZJ-2016-04070},
      pages        = {120},
      year         = {2016},
      abstract     = {Routine diagnostics and treatment monitoring in patients
                      with primary and secondary brain tumors is usually based on
                      contrast-enhanced standard MRI. However, the capacity of
                      standard MRI to differentiate neoplastic tissue from
                      non-specific posttreatment effects may be limited
                      particularly after therapeutic interventions such as radio-
                      and/or chemotherapy or newer treatment options, e.g., immune
                      therapy. Metabolic imaging using PET may provide relevant
                      additional information on tumor metabolism, which allows a
                      more accurate diagnosis especially in clinically equivocal
                      situations, particularly when radiolabeled amino acids are
                      used. Amino acid PET allows a sensitive monitoring of a
                      response to various treatment options, the early detection
                      of tumor recurrence, and an improved differentiation of
                      tumor recurrence from posttherapeutic effects. In the past,
                      this method had only limited availability due to the use of
                      PET tracers with a short half-life, e.g., C-11. In recent
                      years, however, novel amino acid PET tracers labeled with
                      positron emitters with a longer half-life (F-18) have been
                      developed and clinically validated, which allow a more
                      efficient and cost-effective application. These developments
                      and the well-documented diagnostic performance of PET using
                      radiolabeled amino acids suggest that its application
                      continues to spread and that this technique may be available
                      as a routine diagnostic tool for several indications in the
                      field of neuro-oncology.},
      cin          = {INM-3 / INM-4},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406 / I:(DE-Juel1)INM-4-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000381072100001},
      pubmed       = {pmid:27516754},
      doi          = {10.3389/fneur.2016.00120},
      url          = {https://juser.fz-juelich.de/record/811686},
}